BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24737346)

  • 1. A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.
    Wang X; Lin Y; Lan F; Yu Y; Ouyang X; Wang X; Huang Q; Wang L; Tan J; Zheng F
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1399-411. PubMed ID: 24737346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
    Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
    Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
    Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
    Fang WL; Huang KH; Lan YT; Lin CH; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Li AF; Wu CW; Chiou SH; Shyr YM
    Oncotarget; 2016 Feb; 7(5):6201-20. PubMed ID: 26701847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in PI3K/Akt/mTOR pathway genes contribute to gastric cancer risk.
    Ge Y; Liu H; Qiu X; Ma G; Wang H; Du M; Wang M; Zhao Q; Tao G; Chu H; Zhang Z
    Gene; 2018 Sep; 670():130-135. PubMed ID: 29802999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
    Lin L; Zhang Z; Zhang W; Wang L; Wang J
    Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
    Petrini I; Lencioni M; Vasile E; Fornaro L; Belluomini L; Pasquini G; Ginocchi L; Caparello C; Musettini G; Vivaldi C; Caponi S; Ricci S; Proietti A; Fontanini G; Naccarato AG; Nardini V; Santi S; Falcone A
    Cancer Biomark; 2018 Feb; 21(3):731-741. PubMed ID: 29278885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the association between PI3K/AKT/mTOR signaling pathway gene polymorphism and susceptibility to gastric cancer.
    Qi L; Sun K; Zhuang Y; Yang J; Chen J
    J BUON; 2017; 22(6):1488-1493. PubMed ID: 29332342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.
    Zhang Z; Chen Q; Zhang J; Wang Y; Hu X; Yin S; He M; Guan S; Qin W; Xiao Q; Zhao H; Yao W; Wu H; Wei M
    Sci Rep; 2017 Dec; 7(1):17844. PubMed ID: 29259266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without
    Fang WL; Huang KH; Chang SC; Lin CH; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
    Oncologist; 2019 Sep; 24(9):e845-e853. PubMed ID: 30796154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
    Lacey JV; Yang H; Gaudet MM; Dunning A; Lissowska J; Sherman ME; Peplonska B; Brinton LA; Healey CS; Ahmed S; Pharoah P; Easton D; Chanock S; Garcia-Closas M
    Gynecol Oncol; 2011 Feb; 120(2):167-73. PubMed ID: 21093899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.